Stock vs Stock Comparison

Gilead Sciences, Inc. vs Abbott Laboratories

GILD wins the Tale of the Tape 6–3.

GILD$128.99
ABT$86.99

🏆 Tale of the Tape

63
GILDABT
28.9%Profitability (Net Margin)14.7%
18.3xValuation (P/E)24.0x
18.1%Efficiency (ROIC)10.1%
8/9Health (Piotroski F)5/9
4.4Safety (Altman Z)4.9
2.4%Growth (Rev YoY)5.7%
1.02Risk (Sharpe 1Y)-1.05
1.61xBalance Sheet (D/E)0.64x
5.05%FCF Yield4.21%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.184
252-Day Correlation
0.116
126-Day Correlation

Low correlation — excellent diversification pair.

Fundamentals

MetricGILDABT
Market Cap$166.9B$149.1B
P/E Ratio18.3x24.0x
Forward P/E14.0x14.1x
P/B7.10x2.86x
Dividend Yield2.44%2.94%
Beta0.330.65

Quantitative Metrics

MetricGILDABT
DCF Fair Value$190.19$57.20
DCF Upside+36.8%-43.2%
Piotroski F8/95/9
Altman Z4.414.87
Beneish M-2.45-2.53
FCF Yield5.05%4.21%
Net Debt/EBITDA1.1x0.1x
ROIC18.1%10.1%
WACC7.5%9.4%
ROIC – WACC10.6pp0.7pp
Gross Margin78.8%56.4%
Net Margin28.9%14.7%
Rev Growth YoY2.4%5.7%
Sharpe (1Y)1.02-1.05
Max Drawdown 3Y
FCF Payout Ratio42%56%

GILD Price

Loading chart...

ABT Price

Loading chart...

ETF Exposure

GILD found in:

IBB7.35%
XLV3.02%
IYH2.99%
VHT2.63%
HDV2.24%
DGRW1.30%
VFQY1.17%
XBI1.03%
DVY1.01%
QQQ0.84%
MGV0.81%
VIG0.73%
VYM0.68%
VTV0.63%
SCHV0.62%
VFVA0.46%
IWD0.42%
VONV0.36%
ESGV0.35%
QUS0.35%
SCHX0.30%
VFMO0.29%
SCHB0.28%
IVV0.26%
VOO0.26%
SPYV0.26%
SPY0.25%
VONE0.25%
SPLG0.25%
SPYG0.25%
SPTM0.24%
ITOT0.23%
VTI0.23%
RSP0.23%
URTH0.22%
ACWI0.18%
IWF0.17%
VONG0.14%
VT0.14%
ONEO0.13%

ABT found in:

IHI16.06%
IYH2.88%
XLV2.85%
VHT2.55%
DGRW1.71%
XHE1.36%
NOBL1.34%
SDY0.99%
MGV0.78%
VIG0.71%
VFMV0.69%
SCHV0.68%
VYM0.65%
VTV0.61%
IWD0.58%
QUS0.57%
SPYV0.53%
VONV0.48%
IVV0.37%
SPLG0.37%
ESGV0.36%
ITOT0.33%
SCHX0.33%
SCHB0.30%
VOO0.26%
VONE0.24%
SPY0.24%
URTH0.24%
VTI0.23%
SPTM0.22%
ACWI0.20%
RSP0.17%
VT0.14%
ONEO0.08%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

GILD vs ABT: Head-to-Head Analysis

Gilead Sciences, Inc. (GILD) and Abbott Laboratories (ABT) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, GILD leads 6–3 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, GILD generates a return on invested capital (ROIC) of 18.1% compared to ABT's 10.1%. This suggests GILD is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between GILD and ABT is 0.184, indicating low correlation, making them an effective diversification pair in a portfolio context.

GILD appears in 40 ETFs tracked by SecuritiesDB, while ABT appears in 34 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, GILD or ABT?

Our quantitative analysis compares GILD and ABT across nine fundamental dimensions. GILD wins the Tale of the Tape 6–3. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are GILD and ABT correlated?

The 252-day correlation between GILD and ABT is 0.184. They have low correlation, offering good diversification.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.